Carrying the HLA-DQA1*05 allele doubles the risk of developing immunogenicity to anti-TNF therapy and is associated with an increased likelihood of not having a therapeutic response to ulcerative colitis [98,99]. This evidence concerns the gene TNF and ulcerative colitis.